Chronic Migraines vs Regular Headaches: Key Differences, Causes and Complete Treatment Guide
- Dr. Ryan Heals, Pharm.D.
- 1 day ago
- 9 min read
Headache is one of the most universal human experiences — but not all headaches are equal, and understanding the difference between a regular headache and a migraine can be the difference between appropriate treatment and years of unnecessary suffering. According to the WHO, approximately 40% of adults worldwide have a headache disorder, and migraine alone affects more than 3 billion people globally. In the United States, nearly 1 in 6 Americans have experienced a severe headache or migraine in the last three months, and global migraine incidence has increased by approximately 42% over the last 30 years.
Migraine is consistently misunderstood — by patients, by non-specialist clinicians, and by popular culture. It is not simply a "bad headache." It is a complex, genetically influenced neurological disorder characterised by recurrent attacks involving not just head pain but a cascade of neurological symptoms — and it is the second highest cause of years lived with disability worldwide, behind only low-back pain.
Chronic migraine — defined as 15 or more headache days per month for at least 3 months, with at least 8 of those days meeting migraine criteria — affects 3 to 5% of the US population and is one of the most disabling chronic conditions a person can live with.
This complete 2026 guide covers the neuroscience of migraine, how to definitively distinguish migraine from tension headache and other headache types, the four phases of a migraine attack, what causes chronic migraine, and the full treatment landscape from acute triptans to the latest CGRP-targeting biologics.
The NIH StatPearls provides the complete clinical framework for migraine, published in the 2026 January edition at: https://www.ncbi.nlm.nih.gov/books/NBK560787/
What is a Migraine? — The Neuroscience
Migraine is not simply a vascular headache — this outdated theory that migraine was caused by dilating blood vessels has been replaced by a more comprehensive neurological understanding:
The cortical spreading depression (CSD) model:
Migraine attacks begin with cortical spreading depression — a slow wave of neuronal depolarisation (intense electrical activity) followed by prolonged inhibition that spreads across the cerebral cortex at approximately 2–5 mm per minute. This wave of CSD is responsible for the migraine aura — the visual, sensory, or language disturbances that precede headache in approximately 25–30% of migraine patients.
The trigeminovascular pathway:
CSD activates the trigeminovascular system — the trigeminal nerve and its connections to the meningeal blood vessels — triggering release of inflammatory neuropeptides including CGRP (calcitonin gene-related peptide). CGRP causes vasodilation of meningeal vessels and sensitises pain receptors in the meninges. This is why CGRP — and medicines targeting CGRP — are now central to modern migraine treatment.
Why migraine pain is distinctive:
The pain of migraine is transmitted through trigeminal nerve fibres, processed in the brainstem (trigeminal nucleus caudalis), and projected to the thalamus and cortex. Sensitisation of central pain pathways explains why the migraine sufferer becomes hypersensitive to all stimuli — light (photophobia), sound (phonophobia), smell (osmophobia), and even scalp touch (allodynia). These features are not present in ordinary tension headaches and are key diagnostic indicators.
The Four Phases of a Migraine Attack
Understanding that migraine is a multi-phase neurological event — not just a headache — is fundamental:
Phase 1 — Prodrome (hours to days before pain):
Approximately 60–70% of migraine patients experience prodromal symptoms 1–48 hours before the headache begins. These early warning signs include:
Mood changes — irritability, depression, or unusual elation
Food cravings — particularly for sweet or salty foods
Neck stiffness and yawning
Increased urination and thirst
Fatigue and cognitive slowing
Hypersensitivity to light and sound (before the headache phase)
Recognising the prodrome allows patients to take acute medication earlier — before central sensitisation makes treatment less effective.
Phase 2 — Aura (20–60 minutes; present in ~30% of migraineurs):
Aura consists of fully reversible focal neurological symptoms that develop gradually over 5–20 minutes and last no longer than 60 minutes:
Visual aura — the most common; includes scintillating scotoma (a flickering crescent of light that expands across the visual field — the migraine "fortification spectra"), blind spots (scotomata), zigzag lines, or flashing lights
Sensory aura — pins and needles or numbness typically spreading from hand to face
Speech aura — dysphasia or difficulty finding words
Motor aura — rare; weakness on one side; this is migraine with motor aura (hemiplegic migraine)
Important: Aura alone does not mean migraine — migraine without aura (formerly "common migraine") is actually the more prevalent type.
Phase 3 — Headache (4–72 hours):
The defining headache phase. ICHD-3 diagnostic criteria require at least 2 of:
Unilateral location (one side of the head)
Pulsating/throbbing quality
Moderate to severe intensity (limiting normal activity)
Aggravated by routine physical activity
Plus at least 1 of:
Nausea and/or vomiting
Photophobia AND phonophobia
Phase 4 — Postdrome ("migraine hangover" — up to 48 hours):
A post-attack phase in which patients feel exhausted, cognitively "foggy," emotionally flat, or paradoxically elated. The brain has been through a major neurological event — the postdrome reflects the recovery phase. Many patients consider this phase as disabling as the headache itself.
Migraine vs Other Headache Types — Complete Comparison
Feature | Migraine | Tension Headache | Cluster Headache |
Pain quality | Pulsating / throbbing | Pressing / tightening | Excruciating stabbing / boring |
Location | Unilateral (one side) — often | Bilateral ("band" around head) | Always strictly unilateral — around eye |
Severity | Moderate to severe | Mild to moderate | Very severe — "suicide headache" |
Duration | 4–72 hours | 30 min to 7 days | 15–180 minutes |
Nausea/vomiting | Yes — very common | Rarely | Occasionally |
Photophobia + phonophobia | Both — characteristic | One or neither | Mild at most |
Physical activity effect | Worsened by movement | Not worsened | Pacing or rocking REDUCES it |
Aura | 25–30% of patients | No | No |
Autonomic features (eye watering, red eye, nasal congestion) | Occasional | No | Always — hallmark |
Gender predominance | Female (3:1) | Equal | Male (3:1) |
Attack frequency | Variable | Variable | "Cluster" periods of 6–12 weeks |
Prevalence (USA) | ~12% | ~40% | ~0.1% |
Chronic Migraine — Definition and Risk Factors
Chronic migraine is defined by the International Headache Society (IHS) ICHD-3 criteria as:
15 or more headache days per month for at least 3 months
Of which at least 8 per month meet criteria for migraine
Not attributable to medication overuse or another condition
Key distinction: Episodic migraine (fewer than 15 headache days per month) can transform into chronic migraine over time. Approximately 3% of episodic migraineurs make this transition each year.
Risk factors for progression from episodic to chronic migraine:
Medication overuse — the most important and most preventable risk factor; overuse of acute headache treatments (triptans, NSAIDs, opioids, combination analgesics) more than 10–15 days per month causes medication-overuse headache (MOH) and drives chronification
Obesity — significantly increases migraine frequency and severity
Anxiety and depression — bidirectional relationship; each worsens the other
Sleep disorders — insomnia and sleep apnea drive migraine chronification
High caffeine intake
Head injury or neck trauma
Female sex and hormonal fluctuations — oestrogen withdrawal triggers migraine in many women; attacks frequently worsen perimenstrually and perimenopausally
Migraine Triggers — Common and Less Recognised
Trigger Category | Specific Triggers | Notes |
Hormonal | Menstruation (oestrogen drop), oral contraceptive withdrawal, perimenopause | Most potent trigger in women; explains 3:1 female predominance |
Sleep | Too little OR too much sleep; irregular schedule | Maintain consistent sleep-wake times |
Dietary | Skipped meals, dehydration, alcohol (especially red wine and beer), caffeine withdrawal | Not ALL dietary triggers are universal — keep a headache diary |
Sensory | Bright or flickering lights, loud noise, strong smells | Sensory sensitivity is both trigger and symptom |
Stress | Acute stress AND letdown after stress ("weekend migraine") | Stress management and regular scheduling key |
Weather | Barometric pressure changes, strong winds, heat | Hard to modify — can predict risk |
Medications | Nitrates (GTN), oestrogen-containing OCP, some antihypertensives | Review all medications with neurologist |
Physical | Intense exercise (exertional migraine), neck tension, posture | Warm-up gradually; address cervical posture |
Treatment of Migraine — The Complete 2026 Approach
Migraine treatment has two distinct strategies: acute (abort the attack) and preventive (reduce frequency and severity).
Acute Treatment — Aborting the Attack:
Step 1: Simple analgesics (mild-moderate migraine):
Ibuprofen 400–600mg, aspirin 900mg, or paracetamol 1000mg — most effective when taken early in the attack
Combination with antiemetics (metoclopramide, domperidone) improves absorption and reduces nausea
Step 2: Triptans — specific migraine treatment (moderate-severe):
Triptans are serotonin 5-HT1B/1D receptor agonists — they cause constriction of dilated intracranial vessels and inhibit trigeminovascular CGRP release. Seven triptans are available:
Sumatriptan (Imitrex) — first triptan available; oral, nasal, and injectable forms
Rizatriptan (Maxalt) — fast onset; available as rapidly-dissolving wafer
Eletriptan (Relpax) — longer-acting; good for attacks with slow onset
Almotriptan, Naratriptan, Frovatriptan, Zolmitriptan — varying onset and duration
Key principles: Take triptans as early as possible in the headache phase (not during aura); do not overuse (maximum 10 days per month to avoid MOH); contraindicated in cardiovascular disease, stroke, uncontrolled hypertension.
Step 3: CGRP receptor antagonists (Gepants) — newest acute options:
Ubrogepant (Ubrelvy) — FDA-approved 2019; oral; can be used without cardiovascular restrictions
Rimegepant (Nurtec ODT) — FDA-approved 2020; oral dissolving tablet; uniquely approved for BOTH acute and preventive use
Ditans (lasmiditan/Reyvow) — FDA-approved 2019; selective 5-HT1F agonist; no vascular activity; approved for cardiovascular-compromised patients; Schedule V (driving restriction applies).
Preventive Treatment — Reducing Attack Frequency:
Preventive treatment is indicated when migraine significantly impairs quality of life — typically when attacks occur more than 4 days per month, are particularly severe or prolonged, or when acute treatment is overused or poorly effective.
Traditional preventive medicines (taken daily):
Beta-blockers (propranolol, metoprolol) — first-line; reduce attack frequency by approximately 50% in responders
Topiramate (Topamax) — anticonvulsant; FDA-approved for migraine prevention; effective but cognitive side effects common ("dopamax")
Valproate (sodium valproate) — effective but teratogenic; avoid in women of childbearing age
Amitriptyline — low-dose tricyclic antidepressant; particularly helpful when migraine coexists with insomnia or depression
Candesartan / lisinopril — ARB and ACE inhibitor; good tolerability
Pregabalin — used off-label for migraine prevention; particularly useful when migraine coexists with anxiety or neuropathic pain
For patients with anxiety-related migraine where Pregabalin may be appropriate: [Pregabalin for Anxiety: Complete Guide]
CGRP-targeted biologics (moderate-severe chronic migraine):
The most significant advance in migraine treatment in decades — monoclonal antibodies targeting the CGRP pathway:
Erenumab (Aimovig) — targets the CGRP receptor; monthly subcutaneous injection
Fremanezumab (Ajovy) — targets CGRP ligand; monthly or quarterly injection
Galcanezumab (Emgality) — targets CGRP ligand; monthly injection; also approved for cluster headache
Eptinezumab (Vyepti) — targets CGRP ligand; quarterly IV infusion; fastest onset (within days)
All four produce approximately 50% reduction in monthly migraine days in approximately 50% of patients — a transformative result for patients who have failed multiple preventive medications.
OnabotulinumtoxinA (Botox) — FDA-approved specifically for chronic migraine (15+ headache days/month); injected into 31–39 scalp and neck sites every 12 weeks; reduces monthly migraine days by approximately 8–9 days.
The WHO provides a comprehensive global headache disorder fact sheet at: https://www.who.int/news-room/fact-sheets/detail/headache-disorders
For our complete guide on anxiety disorders — which coexist with chronic migraine in approximately 50% of patients and worsen attack frequency: [Anxiety Disorders: Types, Symptoms, Causes and Treatment]
For our guide on depression — which shares bidirectional risk with chronic migraine: [Depression: Symptoms, Causes and Treatment]
For our guide on sleep disorders — insomnia and sleep disruption are among the strongest migraine chronification drivers: [How to Sleep Better: 15 Proven Tips for Insomnia]
The NIH NINDS provides patient-level migraine information at: https://www.ninds.nih.gov/health-information/disorders/migraine
Frequently Asked Questions
How do I know if I have a migraine or just a bad headache?
The key distinguishing features of migraine are: unilateral (one-sided) location, throbbing or pulsating quality, moderate-to-severe intensity that limits normal activity, worsening with movement, and the presence of nausea or vomiting and/or both photophobia and phonophobia simultaneously. Tension headaches are typically bilateral (both sides), pressing rather than throbbing, mild to moderate, and not associated with nausea or significant light and sound sensitivity. If you have attacks that meet migraine criteria and recur regularly, you likely have migraine regardless of whether you have ever received that diagnosis.
What is medication-overuse headache and how does it relate to migraine?
Medication-overuse headache (MOH) — formerly called "rebound headache" — occurs when acute headache medications are used on too many days per month. The threshold varies by drug type: triptans and opioids cause MOH if used on 10 or more days per month; simple analgesics and NSAIDs if used on 15 or more days per month. MOH causes a vicious cycle — the headache returns as the medication wears off, driving further use. It affects up to 5 percent of the population and is one of the most important preventable causes of chronic daily headache. Treatment requires gradual withdrawal of the overused medication under medical supervision.
Can migraines be cured?
Migraine cannot be cured — it is a lifelong neurological condition influenced by genetics. However, it can be very effectively managed. With the right combination of trigger identification, lifestyle optimisation, acute treatment taken appropriately, and — where needed — preventive treatment including the new CGRP monoclonal antibodies, most people with migraine can achieve a dramatic reduction in attack frequency and severity. Many patients with chronic migraine successfully transition back to episodic migraine with appropriate treatment.
Are migraines more common in women?
Yes — significantly. Migraine affects women approximately three times more often than men after puberty. Before puberty, migraine prevalence is equal between sexes. The female predominance is driven by oestrogen — fluctuations in oestrogen levels across the menstrual cycle, with oral contraceptives, during pregnancy, and at perimenopause are powerful migraine triggers. Menstrual migraine — occurring in the days immediately before and during menstruation when oestrogen levels drop sharply — is one of the most severe and treatment-resistant migraine subtypes.
What is the difference between episodic and chronic migraine?
Episodic migraine is defined as fewer than 15 headache days per month — most people with migraine have episodic migraine. Chronic migraine is defined as 15 or more headache days per month for at least 3 consecutive months, with at least 8 of those days meeting migraine diagnostic criteria. Chronic migraine is more disabling, harder to treat, and strongly associated with medication overuse, obesity, anxiety, depression, and sleep disorders. The distinction matters because chronic migraine warrants a different treatment approach — preventive therapy is always indicated and CGRP biologics and Botox are specifically approved for this form.
Comments